Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2470)	1/22/2009 1:23:59 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CEPH is trying gto get back to the $80 level. :>) After the downward pressure of the general market and all the problems with the global economy, it is hard to find a biotech or any other company with chances of testing its all time H, and CEPH is among that rare or very exclusive group. And that is in spite of its large institutional following as many institutions have been forced to sell some of their winning stocks in order to raise cash. finance.yahoo.com But CEPH has a good amount of +CF and +FCF and earnings in 2008 are expected to be 20% better than in 2007 with another 20% improvement expected for 2009 Last week it announced that it had signed an agreement with Ception Therapeutics, providing CEPH with an option to purchase Ception. CEPH will pay Ception a $100M upfront and a total of $250M when it decides to complete the acquisition. Ception's lead product is reslizumab, a humanized monoclonal antibody against IL-5, which is currently in a PIIb/III for pediatric eosinophilic esophagitis and in a PII for eosinophilic asthma in adults. It also has a program to discover small molecule, orally-active, anti-TNF receptor agents. At any rate,it seems that CEPH wants to test its all time H on June 2007 at the $84.83 level. :>) Bernard

To: Jibacoa who wrote (2470)	10/16/2009 10:12:40 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

TRGT opened with a nice UG after it announced after th market close yesterday data from its recently completed PII2b of TC-5214 as an add-on treatment in subjects with major depressive disorder who did not respond adequately to treatment with the representative SSRI citalopram hydrobromide. The add-on TC-5214 arm outperformed the add-on placebo arm on the primary outcome measure and all of the secondary outcome measures, with high statistical significance.<g> The stock has had a very good UT with a nice % gain since my previous note in January and its previous UG on July 15. <G> bigcharts.marketwatch.com The stock is making another ATH bigcharts.marketwatch.com Bernard